Pipeline
Cornerstone’s lead compound, CPI-613® (devimistat), is being evaluated in clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with rare solid tumors or blood cancers.
Cornerstone’s lead compound, CPI-613® (devimistat), is being evaluated in clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with rare solid tumors or blood cancers.